Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMMX

Immix Biopharma, Inc.

Healthcare · Biotechnology

$10.13

Down-$0.49 (-4.84%)

Updated Oct 7, 2026, 1:51 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
246.93M
P/E ratio
-9.97
Dividend yield
0.00%
52-week range
$7.65 – $15.10
Volume
1.6M
Avg. volume
730.89K

Price performance · IMMX

IMMX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

IMMX closed at $10.13 after 20 trading sessions, down 23.55% for the selected period.

Last close
$10.13
Period change
-23.55%
Period low
$9.68
Period high
$13.25
Daily close
View OHLC price history
IMMX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$9.71$10.33$9.55$10.131.6M
Oct 2, 2026$10.35$10.37$9.48$9.682.55M
Oct 1, 2026$10.25$10.475$9.86$10.231.65M
Sep 30, 2026$10.61$11.25$10.3925$10.4052.41M
Sep 29, 2026$11.64$11.848$10.07$10.545.76M
Sep 28, 2026$10.82$11.84$10.70$11.47995.93K
Sep 25, 2026$11.78$11.9899$10.82$10.971.83M
Sep 24, 2026$11.87$11.97$11.185$11.701.54M
Sep 23, 2026$12.80$12.84$11.71$11.921.17M
Sep 22, 2026$12.45$12.90$12.31$12.83948.5K
Sep 21, 2026$12.59$12.71$12.14$12.471.33M
Sep 18, 2026$12.68$12.84$12.34$12.504.18M
Sep 17, 2026$12.24$12.75$12.07$12.721.19M
Sep 16, 2026$12.28$12.46$11.7501$11.921.42M
Sep 15, 2026$12.49$12.63$11.81$12.141.05M
Sep 14, 2026$12.44$12.59$11.98$12.211.08M
Sep 11, 2026$12.86$13.29$12.02$12.141.19M
Sep 10, 2026$12.08$12.77$11.91$12.701.66M
Sep 9, 2026$13.12$13.23$12.24$12.311.29M
Sep 8, 2026$13.70$13.89$12.75$13.251.42M

Latest IMMX news

The latest Smart Investors Daily articles mentioning IMMX.

Stock researchCompany · Overview

IMMX research

Overview

Company profile and research snapshot.

Company profile

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
IMMX recent ratings
DateFirmRatingTarget
Sep 29, 2026NeedhamBuy—
Sep 15, 2026MizuhoOutperform—
Aug 11, 2026Morgan StanleyOverweight—
Aug 10, 2026HC Wainwright & Co.Buy—
Jul 22, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

– Financing includes leading U.S. biotechnology institutional investors and mutual funds –LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The net proceeds to Immix from the offering, after ded

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By